Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease.
Two human immunodeficiency virus-infected patients who needed etoposide therapy to control exacerbations of Castleman disease received four infusions of rituximab. Clinical and virologic relapses with increased blood human herpesvirus-8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma.
Neuville
Ségolène
S
Department of Infectious Diseases, Saint-Louis Hospital, University of Paris, AP-HP, Paris, France.
Agbalika
Felix
F
Rabian
Claire
C
Brière
Josette
J
Molina
Jean-Michel
JM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000097:blood; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005871:Castleman Disease / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D004279:DNA, Viral / Q000097:blood; D015658:HIV Infections / Q000150:complications* / Q000821:virology; D019288:Herpesvirus 8, Human / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D012514:Sarcoma, Kaposi / Q000150:complications* / Q000821:virology; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D004279:DNA, Viral; D000069283:Rituximab